A new national trial is recruiting people with rare autoimmune diseases to measure their COVID-19 antibody response following at least 3 vaccinations.
The MELODY study is recruiting immunocompromised people to determine the antibody levels they develop in response to COVID-19 vaccination.
The MELODY study aims to:
- Assess how many immunocompromised people have detectable antibodies against COVID-19 following at least 3 vaccines;
- Investigate whether a lack of detectable antibodies is associated with risk of infection over a 6-month period;
- Investigate what factors are associated with lack of detectable antibodies in immunocompromised people.
Read more of this article